ALNYLAM PHARMACEUTICALS, INC. Cash & Equivalents 2007-2025 | ALNY
What is cash & equivalents?
Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.
What is ALNYLAM PHARMACEUTICALS, INC.'s current cash & equivalents?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual cash & equivalents for 2025 was $1.66B, a 71.48% increase from 2024. ALNYLAM PHARMACEUTICALS, INC. cash & equivalents for the quarter ending December 31, 2025 was $1.66B.
What was ALNYLAM PHARMACEUTICALS, INC.'s cash & equivalents in 2024?
ALNYLAM PHARMACEUTICALS, INC. annual cash & equivalents for 2024 was $966.4M, a 18.92% increase from 2023.
What was ALNYLAM PHARMACEUTICALS, INC.'s cash & equivalents in 2023?
ALNYLAM PHARMACEUTICALS, INC. annual cash & equivalents for 2023 was $812.7M, a 6.20% decline from 2022.
What is ALNYLAM PHARMACEUTICALS, INC.'s 5-year cash & equivalents CAGR?
ALNYLAM PHARMACEUTICALS, INC. cash & equivalents grew at a compound annual growth rate (CAGR) of 27.26% from FY2020 to FY2025, going from $496.6M to $1.66B over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $1.66B | +71.5% | 10-K |
| FY2024 | $966.4M | +18.9% | 10-K |
| FY2023 | $812.7M | -6.2% | 10-K |
| FY2022 | $866.4M | +5.7% | 10-K |
| FY2021 | $820.0M | +65.1% | 10-K |
| FY2020 | $496.6M | -9.2% | 10-K |
| FY2019 | $547.2M | +30.2% | 10-K |
| FY2018 | $420.1M | -34.9% | 10-K |
| FY2017 | $645.4M | +233.3% | 10-K |
| FY2016 | $193.6M | +7.0% | 10-K |
| FY2015 | $180.9M | +140.6% | 10-K |
| FY2014 | $75.2M | +41.4% | 10-K |
| FY2013 | $53.2M | +3.4% | 10-K |
| FY2012 | $51.4M | -26.8% | 10-K |
| FY2011 | $70.2M | -5.9% | 10-K |
| FY2010 | $74.6M | -45.7% | 10-K |
| FY2009 | $137.5M | -28.3% | 10-K |
| FY2008 | $191.8M | +82.4% | 10-K |
| FY2007 | $105.2M | - | 10-K |